Daily Stock Analysis, CBLI, Cleveland Biolabs Inc, priceseries

Cleveland Biolabs Inc. Daily Stock Analysis
Stock Information
Open
1.56
Close
1.62
High
1.64
Low
1.54
Previous Close
1.56
Daily Price Gain
0.06
YTD High
2.06
YTD High Date
Feb 21, 2017
YTD Low
1.35
YTD Low Date
Mar 17, 2017
YTD Price Change
0.17
YTD Gain
11.72%
52 Week High
3.30
52 Week High Date
Jun 28, 2016
52 Week Low
1.22
52 Week Low Date
Dec 29, 2016
52 Week Price Change
-0.97
52 Week Gain
-37.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 26. 2015
3.25
May 27. 2015
3.69
1 Trading Days
13.69%
Link
LONG
Jun 25. 2015
5.38
Jun 26. 2015
5.71
1 Trading Days
6.04%
Link
LONG
Aug 28. 2015
3.80
Sep 25. 2015
4.67
19 Trading Days
23.03%
Link
Company Information
Stock Symbol
CBLI
Exchange
NasdaqCM
Company URL
http://www.cbiolabs.com
Company Phone
(716) 849-6810
CEO
Yakov Kogan
Headquarters
New York
Business Address
73 HIGH STREET, BUFFALO, NY 14203
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001318641
About

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for ...

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.